Register
Forgot your password?

Risk factors of recurrent atrial fibrillation after catheter ablation

Authors: Romanchuk D.V., Khotsanyan C.V., Arakelyan M.G.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2023-17-1-50-64

For citation: Romanchuk D.V., Khotsanyan C.V., Arakelyan M.G. Risk factors of recurrent atrial fibrillation after catheter ablation. Creative Cardiology. 2023; 17 (1): 50–64 (in Russ.). DOI: 10.24022/1997-3187-2023-17-1-50-64

Received / Accepted:  13.03.2023 / 29.03.2023

Keywords: atrial fibrillation catheter ablation comorbidity recurrence fibrosis natriuretic peptide



Subscribe 🔒

 

Abstract

Atrial fibrillation (AF) is one of the most widespread heart rhythm disorders, the frequency in developed countries is about 0,5%. Currently the number of hospitalizations (from 435.7 to 1227 thousand per year) and cost of treatment for AF are still increasing in Russia (on average 17 billion rubles for the hospital treatment per year). It is happening because of improvement of treatment algorithms, using new medications, and upgrading of surgical and interventional techniques. According to modern clinical guidelines, one of the most effective ways for rhythm control is pulmonary vein catheter ablation. But efficiency of this method is from 52 to 80%. Considering the high rate of AF recurrence, even in patients without significant cardiovascular diseases, searching of predictors of better outcome for catheter ablation is most pressing challenge. In this article the modern view on the problem of resumed AF after intervention strategies is performed, including modern predictors, such as echocardiography parameters, magnetic-resonance imaging, brain natriuretic peptide (BNP) level and results of cardiopulmonary exercise testing

References

  1. Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Intern. J. Stroke. 2021; 16 (2): 217–21. DOI: 10.1177/1747493019897870.
  2. Al-Khatib S.M., Benjamin E.J., Buxton A.E., Calkins H., Chung M.K., Curtis A.B. et al. Research needs and priorities for catheter ablation of atrial fibrillation: a report from a national heart, lung, and blood institute virtual workshop. Circulation. 2020; 141 (6): 482–92. DOI: 10.1161/CIRCULATIONAHA.119.042706
  3. Calkins H., Hindricks G., Cappato R., Kim Y.H., Saad E.B., Aguinaga L. et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14 (10): 275–444. DOI: 10.1016/j.hrthm.2017.05.012
  4. Habibi M., Calkins H. Atrial fibrillation catheter ablation: an updated review of current guidelines and expert consensus documents. Herz. Elektrophysiol. 2019; 30 (4): 371–6. DOI: 10.1007/s00399-019-00651-0
  5. Arakelyan M.G., Bockeria LA., Vasilieva E.Yu., Golitsyn E.Z., Golukhova E.Z., Gorev M.V. et al. 2020 Clinical guidelines for atrial fibrillation and atrial flutter. Russian Journal of Cardiology. Silicea – Poligraf., LLC., 2021; 26 (7): 4594 (in Russ.). DOI: 10.15829/1560-4071-2021-4594
  6. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort: the framingham heart study. JAMA: J. Am. Med. Assoc. 1994; 271 (11): 840–4.
  7. Leong-Sit P., Zado E., Callans D.J., Garcia F., Lin D., Dixit S., Bala R. et al. Efficacy and risk of atrial fibrillation ablation before 45 years of age. Circ. Arrhythm. Electrophysiol. 2010; 3 (5): 452–7. DOI: 10.1161/CIRCEP.110.938860
  8. Bunch T.J., May H.T., Bair T.L., Jacobs V., Crandall B.G., Cutler M. et al. The impact of age on 5-year outcomes after atrial fibrillation catheter ablation. J. Cardiovasc. Electrophysiol. 2016; 27 (2): 141–6. DOI: 10.1111/jce.12849
  9. Zink M.D., Chua W., Zeemering S., di Biase L., Antoni B.L., David C. et al. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace. 2020; 22 (9): 1337–44. DOI: 10.1093/europace/euaa132
  10. Winkle R.A., Jarman J.W., Mead R.H., Engel G., Kong M.H., Fleming W. et al. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart Rhythm. 2016; 13 (11): 2119–25. DOI: 10.1016/j.hrthm.2016.07.018
  11. Kautzner J., Peichl P., Sramko M., Cihak R., Aldhoon B., Wichterle D. Catheter ablation of atrial fibrillation in elderly population. J. Geriatric. Cardiol. 2017; 14 (9): 563–8. DOI: 10.11909/j.issn.1671-5411.2017.09.008
  12. Vanhees L., Geladas N., Hansen D., Kouidi E., Niebauer J., Reiner Z. et al. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II). Eur. J. Prevent. Cardiol. 2012; 19 (5): 1005–33. DOI: 10.1177/1741826711430926
  13. Pathak R.K., Elliott A., Middeldorp M.E., Meredith M., Mehta A.B., Mahajan R. et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation the CARDIO-FIT study. J. Am. Coll. Cardiol. 2015; 66 (9): 985–96. DOI: 10.1016/j.jacc.2015.06.488
  14. Donnellan E., Wazni O.M., Harb S., Kanj M., Saliba W.I., Jaber W.A. Higher baseline cardiorespiratory fitness is associated with lower arrhythmia recurrence and death after atrial fibrillation abla60 Creative Cardiology. 2023; 17 (1) DOI: 10.24022/1997-3187-2023-17-1-50-64 Reviews tion. Heart Rhythm. 2020; 17 (10): 1687–93. DOI: 10.1016/j.hrthm.2020.05.013
  15. Pathak R.K., Middeldorp M.E., Meredith M., Mehta A.B., Mahajan R., Wong C.X. et al. Longterm effect of goal-directed weight management in an atrial fibrillation cohort: A long-term follow-up study (LEGACY). J. Am. Coll. Cardiol. 2015; 65 (20): 2159–69. DOI: 10.1016/j.jacc.2015.03.002
  16. Proietti R., Birnie D., Ziegler P.D., Wells G.A., Verma A. Postablation atrial fibrillation burden and patient activity level: Insights from the DISCERN AF study. J. Am. Heart Assoc. 2018; 7 (23): e010256. DOI: 10.1161/JAHA.118.010256
  17. Mohanty S., Mohanty P., Natale V., Trivedi C., Gianni C., Burkhardt J.D. et al. Impact of weight loss on ablation outcome in obese patients with longstanding persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. 2018; 29 (2): 246–53. DOI: 10.1111/jce.13394
  18. Mandsager K.T., Phelan D.M., Diab M., Baranowski B., Saliba W.I., Tarakji K.G. et al. Outcomes of pulmonary vein isolation in athletes. JACC Clin. Electrophysiol. 2020; 6 (10): 1265–74. DOI: 10.1016/j.jacep.2020.05.009
  19. Mohanty S., Mohanty P., Tamaki M., Natale V., Gianni C., Trivedi C. et al. Differential association of exercise intensity with risk of atrial fibrillation in men and women: evidence from a meta-analysis. J. Cardiovasc. Electrophysiol. 2016; 27 (9): 1021–9. DOI: 10.1111/jce.13023
  20. Zhang H.Z., Shao B., Wang Q.Y., Wang Y.H., Cao Z.Z., Chen L.L. Alcohol consumption and risk of atrial fibrillation: a dose-response metaanalysis of prospective studies. Front. Cardiovasc. Med. 2022; 9: 281–9 DOI: 10.3389/fcvm.2022.802163
  21. Qiao Y., Shi R., Hou B., Wu L., Zheng L., Ding L. et al. Impact of alcohol consumption on substrate remodeling and ablation outcome of paroxysmal atrial fibrillation. J. Am. Heart Assoc. 2015; 4 (11): e002349. DOI: 10.1161/JAHA.115.002349
  22. Pathak R.K., Middeldorp M.E., Lau D.H., Mehta A.B., Mahajan R., Twomey D. et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J. Am. Coll. Cardiol. 2014; 64 (21): 2222–31. DOI: 10.1016/j.jacc.2014.09.028
  23. Sivasambu B., Balouch M.A., Zghaib T., Bajwa R.J., Chrispin J., Berger R.D. et al. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients. J. Cardiovasc. Electrophysiol. 2018; 29 (2): 239–45. DOI: 10.1111/jce.13388 24. Guglin M., Maradia K., Chen R., Curtis A.B. Relation of obesity to recurrence rate and burden of atrial fibrillation. Am. J. Cardiol. 2011; 107 (4): 579–82. DOI: 10.1016/j.amjcard.2010.10.018
  24. Mohanty S., Mohanty P., Di Biase L., Bai R., Pump A., Santangeli P. et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J. Am. Coll. Cardiol. 2012; 59 (14): 1295–301. DOI: 10.1016/j.jacc.2011.11.051
  25. Ng C.Y., Liu T., Shehata M., Stevens S., Chugh S.S., Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am. J. Cardiol. 2011; 108 (1): 47–51. DOI: 10.1016/j.amjcard.2011.02.343
  26. Matiello M., Nadal M., Tamborero D., Berruezo A., Montserrat J., Embid C. et al. Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace. 2010; 12 (8); 1084–9. DOI: 10.1093/europace/euq128
  27. Zhao Y., Di Biase L., Trivedi C., Mohanty S., Bai R., Mohanty P. et al. Importance of non-pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction. Heart Rhythm. 2016; 13 (1): 141–9. DOI: 10.1016/j.hrthm.2015.08.029
  28. Khaykin Y., Oosthuizen R., Zarnett L., Essebag V., Parkash R., Seabrook C. et al. Clinical predictors of arrhythmia recurrences following pulmonary vein antrum isolation for atrial fibrillation: Predicting arrhythmia recurrence post-PVAI. J. Cardiovasc. Electrophysiol. 2011; 22 (11): 1206–14. DOI: 10.1111/j.1540-8167.2011.02108.x
  29. Anselmino M., Matta M., D'Ascenzo F., Bunch T.J., Schilling R.J., Hunter R.J. et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and metaanalysis. Circ. Arrhythm. Electrophysiol. 2014; 7 (6): 1011–8. DOI: 10.1161/CIRCEP.114.001938
  30. Creta A., Providência R., Adragão P., de Asmundis C., Chun J., Chierchia G. et al. Impact of type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation (european observational multicentre study). Am. J. Cardiol. 2020; 125 (6): 901–6. DOI: 10.1016/j.amjcard. 2019.12.037
  31. Mohanty S., Mohanty P., DI Biase L., Bai R., Trivedi C., Santangeli P. et al. Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and obstructive sleep apnea: impact of repeat procedures versus lifestyle changes. J. Cardiovasc. Electrophysiol. 2014; 25 (9): 930–8. DOI: 10.1111/jce.12468
  32. Brachmann J., Sohns C., Andresen D., Siebels J., Sehner S., Boersma L. et al. Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF Trial. JACC Clin. Electrophysiol. 2021; 7 (5): 594–603. DOI: 10.1016/j.jacep.2020.11.021
  33. Noseworthy P.A., Van Houten H.K., Gersh B.J., Packer D.L., Friedman P.A., Shah N.D. et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020; 17 (7): 1057–65. DOI: 10.1016/j.hrthm.2020.02.030
  34. Di Biase L., Mohanty P., Mohanty S., Santangeli P., Trivedi C., Lakkireddy D.P. et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133 (17): 1637–44. DOI: 10.1161/CIRCULATIONAHA.115.019406
  35. D'Ascenzo F., Corleto A., Biondi-Zoccai G., Anselmino M., Ferraris F., di Biase L. et al. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation? A meta-analysis. Int. J. Cardiol. 2013; 167 (5): 1984–9. DOI: 10.1016/j.ijcard.2012.05.008
  36. Andrade J.G., Deyell M.W., Verma A., Macle L., Champagne J., Leong-Sit P. et al. Association of atrial fibrillation episode duration with arrhythmia recurrence following ablation: a secondary analysis of a randomized clinical trial. JAMA Netw. Open. 2020; 3 (7): e208748. DOI: 10.1001/jamanetworkopen.2020.8748
  37. Kirchhof P., Camm A.J., Goette A., Brandes A., Eckardt L., Elvan A. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 2020; 383 (14): 1305–16. DOI: 10.1056/NEJMoa2019422
  38. Low S.K., Takahashi A., Ebana Y., Ozaki K., Christophersen I.E., Ellinor P.T. et al. Identification of six new genetic loci associated with atrial fibrillation in the Japanese population. Nat. Genet. 2017; 49 (6): 953–8. DOI: 10.1038/ng.3842
  39. Shoemaker M.B., Husser D., Roselli C., Al Jazairi M., Chrispin J., Kühne M. et al. Genetic Susceptibility for atrial fibrillation in patients undergoing atrial fibrillation ablation. Circ. Arrhythm. Electrophysiol. 2020; 13 (3): e007676. DOI: 10.1161/CIRCEP.119.007676
  40. Sanchez-Somonte P., Jiang C.Y., Betts T.R., Chen J., Mantovan R., Macle L. et al. Completeness of linear or fractionated electrogram ablation in addition to pulmonary vein isolation on ablation outcome: a substudy of the STAR AF II trial. Circ. Arrhythm. Electrophysiol. 2021; 14 (9): e010146. DOI: 10.1161/CIRCEP.121.010146
  41. Charitakis E., Dragioti E., Stratinaki M., Korela D., Tzeis S., Almroth H. Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses. Europace. 2023; 25 (1): 40–8. DOI: 10.1093/europace/euac143
  42. Della Rocca D.G., Di Biase L., Mohanty S., Trivedi C., Gianni C., Romero J. et al. Targeting non-pulmonary vein triggers in persistent atrial fibrillation: Results from a prospective, multicentre, observational registry. Europace. 2021; 23 (12): 1939–49. DOI: 10.1093/europace/euab161 44. Di Biase L., Burkhardt J.D., Mohanty P., Mohanty S., Sanchez J.E., Trivedi C. et al. Left atrial appendage isolation in patients with longstanding persistent AF undergoing catheter ablation: BELIEF Trial. J. Am. Coll. Cardiol. 2016; 68 (18): 1929–40. DOI: 10.1016/j.jacc.2016.07.770
  43. Takamiya T., Inaba O., Nitta J., Sato A., Inamura Y., Murata K. et al. Association between the locations of non-pulmonary vein triggers and ablation outcomes in repeat procedures after cryoballoon ablation of paroxysmal atrial fibrillation. J. Intervent. Cardiac. Electrophysiol. 2021; 62 (2): 381–9. DOI: 10.1007/s10840-020-00913-9
  44. Yavin H.D., Leshem E., Shapira-Daniels A., Sroubek J., Barkagan M., Haffajee C.I. et al. Impact of high-power short-duration radiofrequency ablation on long-term lesion durability for atrial fibrillation ablation. JACC Clin. Electrophysiol. 2020; 6 (8): 973–85. DOI: 10.1016/j.jacep.2020.04.023
  45. Avanesyan G.A., Saparbaev A.A., Filatov A.G., Kovalev A.S., Shalov R.Z. Pulsed field ablation in thetreatment of atrial fibrillation. Creative Cardiology. 2021; 15 (3): 332–41 (in Russ.). DOI: 10.24022/1997-3187-2021-15-3-332-341
  46. Reddy V.Y., Anic A., Koruth J., Petru J., Funasako M., Minami K. et al. Pulsed field ablation in patients with persistent atrial fibrillation. J. Am. Coll. Cardiol. 2020; 76 (9): 1068–80. DOI: 10.1016/j.jacc.2020.07.007
  47. Parikh V., Swarup V., Hantla J., Vuddanda V., Dar T., Yarlagadda B. et al. Feasibility, safety, and efficacy of a novel preshaped nitinol esophageal deviator to successfully deflect the esophagus and ablate left atrium without esophageal temperature rise during atrial fibrillation ablation: The DEFLECT GUT study. Heart Rhythm. 2018; 15 (9): 1321–7. DOI: 10.1016/j.hrthm.2018.04.017
  48. Liżewska-Springer A., Dabrowska-Kugacka A., Lewicka E., Drelich Ł., Królak T., Raczak G. Echocardiographic predictors of atrial fibrillation recurrence after catheter ablation: a literature review. Cardiol. J. 2020; 27 (6): 848–56. DOI: 10.5603/CJ.a2018.0067
  49. Mollaeva D.D., Mashina T.V., Mrikaev D.V., Berdibekov B.Sh., Filatov A.G., Golukhova E.Z. Modern ultrasound techniques in the assessment of left atrium structural abnormalities in patients with atrial fibrillation. Creative Cardiology. 2021; 15 (1): 48–60 (in Russ.). DOI: 10.24022/1997-3187- 2021-15-1-48-60
  50. Njoku A., Kannabhiran M., Arora R., Reddy P., Gopinathannair R., Lakkireddy D., Dominic P. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis. Europace. 2018; 20 (1): 33–42. DOI: 10.1093/europace/eux013
  51. Shimamoto K., Miura F., Shimatani Y., Nishioka K., Inoue I. Pulmonary vein volume predicts the outcome of radiofrequency catheter ablation of paroxysmal atrial fibrillation. PLoS One. 2018; 13 (7): e0201199. DOI: 10.1371/journal.pone.0201199
  52. Nakamura K., Takagi T., Kogame N., Asami M., Toyoda Y., Enomoto Y. et al. Impact of atrial mitral and tricuspid regurgitation on atrial fibrillation recurrence after ablation. J. Electrocardiol. 2021; 66: 114–21. DOI: 10.1016/j.jelectrocard.2021. 04.005
  53. Bergonti M., Spera F.R., Ferrero T.G., Nsahlai M., Bonomi A., Tijskens M. Characterization of atrial substrate to predict the success of pulmonary vein isolation: the prospective, multicenter MASH-AF II (Multipolar Atrial Substrate High density mapping in Atrial Fibrillation) Study. J. Am. Heart Assoc. 2023; 12 (1): e027795. DOI: 10.1161/JAHA.122.027795
  54. Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA. J. Am. Med. Assoc. 2014; 311 (5): 498–506. DOI: 10.1001/jama.2014.3
  55. Hayashi K., An Y., Nagashima M., Hiroshima K., Ohe M., Makihara Y. et al. Importance of nonpulmonary vein foci in catheter ablation for paroxysmal atrial fibrillation. Heart Rhythm. 2015; 12 (9): 1918–24. DOI: 10.1016/j.hrthm.2015.05.003
  56. Takigawa M., Takahashi A., Kuwahara T., Okubo K., Takahashi Y., Nakashima E. et al. Impact of nonpulmonary vein foci on the outcome of the second session of catheter ablation for paroxysmal atrial fibrillation. J. Cardiovasc. Electrophysiol. 2015; 26 (7): 739–46. DOI: 10.1111/jce.12681
  57. Takamiya T., Inaba O., Nitta J., Sato A., Inamura Y., Murata K. et al. Association between the locations of non-pulmonary vein triggers and ablation outcomes in repeat procedures after cryoballoon ablation of paroxysmal atrial fibrillation. J. Intervent. Card. Electrophysiol. 2021; 62 (2): 381–9. DOI: 10.1007/s10840-020-00913-9
  58. Degener S., Pattberg S.V., Feuersenger H., Bansmann P.M., Shin D.I., Krummenauer F. et al. Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation. J. Interv. Card. Electrophysiol. 2011; 30 (3): 217–25. DOI: 10.1007/s10840-010-9540-2
  59. Hussein A.A., Saliba W.I., Martin D.O., Shadman M., Kanj M., Bhargava M. et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011; 123 (19): 2077–82. DOI: 10.1161/CIRCULATIONAHA.110.007252
  60. Pillarisetti J., Reddy N., Biria M., Ryschon K., Nagarajan D., Murray C. et al. Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: Is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time? J. Interv. Card. Electrophysiol. Kluwer Academic Publishers. 2014; 40 (2): 161–8. DOI: 10.1007/s10840-014-9898-7
  61. Xu X., Tang Y. Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: An updated meta-analysis. Br. J. Cardiovasc. Surg. 2017; 32 (6): 530–5. DOI: 10.21470/1678-9741-2017-0008
  62. Matsumoto S., Matsunaga-Lee Y., Ishimi M., Ohnishi M., Masunaga N., Tachibana K. et al. Clinical Significance of B-Type natriuretic peptide levels at 3 months after atrial fibrillation ablation. Diseases. MDPI AG. 2021; 9 (3): 49. DOI: 10.3390/diseases9030049
  63. Baba M., Yoshida K., Naruse Y., Hattori A., Yui Y., Kimata A. et al. Predictors of recurrence after catheter ablation of paroxysmal atrial fibrillation in different follow-up periods. Medicina (Lithuania). MDPI AG. 2020; 56 (9): 1–15. DOI: 10.3390/medicina56090465
  64. Fukasawa K., Fukuda K., Mori N., Kondo M., Chiba T., Miki K. et al. Impacts of sinus rhythm maintenance with catheter ablation on exercise tolerance in patients with paroxysmal atrial fibrillation. J. Intervent. Card. Electrophysiol. 2021; 61 (1). 105–13. DOI: 10.1007/s10840-020-00786-y
  65. Yamashita D., Kamikawa S., Tanaka R., Tabita N., Nishimura S., Mitsuoka M. et al. Correlation of the peak oxygen consumption and ventilatory aerobic threshold by cardiopulmonary exercise testing with atrial fibrillation recurrences after ablation in patients with paroxysmal atrial fibrillation. J. Arrhythm. 2020; 36 (3): 456–63. DOI: 10.1002/joa3.12350
  66. Mujović N.M., Marinković M.M., Nedeljković I., Marković N., Banović M., Vučićević V. et al. Improvement of maximal exercise performance after catheter-ablation of atrial fibrillation and its prognostic significance for long-term rhythm outcome. J. Am. Heart Assoc. Am. Heart Association Inc. 2021; 10 (3): 1–11. DOI: 10.1161/JAHA.120.017445
  67. Tsuneoka H., Koike A., Nagayama O., Sakurada K., Kato J., Sato A., Yamashita T., Aonuma K. Prog-nostic value of cardiopulmonary exercise testing in cardiac patients with atrial fibrillation. Int. Heart J. 2012; 53 (2): 102–7. DOI: 10.1536/ihj.53.102
  68. Kuan P.X., Chan W.K., Fern Ying D.K., Rahman M.A.A., Peariasamy K.M., Lai N.M. et al. Efficacy of telemedicine for the management of cardiovascular disease: a systematic review and meta-analysis. Dig. Health Res. Inn. 2022; 4: 676–91. DOI: 10.1016/S2589-7500(22)00124-8

About Authors

  • Denis V. Romanchuk, Postgraduate; ORCID
  • Chinara V. Khotsanyan, Cand. Med. Sci., Cardiologist; ORCID
  • Mari G. Arakelyan, Researcher, Cardiologist; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by